Source: European Parliament
Question for written answer E-001185/2025
to the Commission
Rule 144
Laurent Castillo (PPE)
The Commission’s decision to retaliate against the United States’ trade measures was both necessary and a question of principle, as American tariffs cannot be allowed to undermine the economic interests of the EU’s industrial and agricultural sectors.
However, by including medical technologies and their components in its list of targeted US products, the Commission could end up harming not only the EU’s medical device industry, but also the innovation and supply chains of a sector that is already having to cope with two administratively burdensome regulations.
To make matters worse, the Commission’s response could discourage research investment and drive up the cost of accessing medical devices, thus undermining public health in the EU.
Exempting medical devices from tariff measures is therefore vital to ensuring that European patients can continue to access high-quality healthcare and that the EU’s medical device industry can attract investors.
What measures will the Commission put in place to guarantee that EU and US tariffs do not target medical devices or affect their supply chains?
Submitted: 20.3.2025